- American Psychiatric Association. Neurocognitive disorders. In: Diagnostic and Statistical Manual of Mental Disorders. 5th ed. APA; 2013.
World Health Organization. Dementia. https://www.who.int/news-room/fact-sheets/detail/dementia
- American Psychiatric Association. Neurocognitive disorders. In: Diagnostic and Statistical Manual of Mental Disorders. 5th ed. Text Revision. American Psychiatric Association; 2022.
Petersen RC, Lopez O, Armstrong MJ. Practice guideline update summary: mild cognitive impairment: report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. Neurology. 2018;90(3):126-135.
Knopman DS, Petersen RC. Mild cognitive impairment and mild dementia: a clinical perspective. Mayo Clin Proc. 2014;89(10):1452-1459.
Obuchowski NA, Graham RJ, Baker ME, Powell KA. Ten criteria for effective screening: their application to multislice CT screening for pulmonary and colorectal cancers. AJR Am J Roentgenol. 2001;176(6):1357-1362.
Owens DK, Davidson KW, Krist AH. Screening for cognitive impairment in older adults: US Preventive Services Task Force Recommendation Statement. JAMA. 2020;323(8):757-763.
American Academy of Family Physicians. Clinical preventive service recommendation. Dementia. https://www.aafp.org/family-physician/patient-care/clinical-recommendations/all-clinical-recommendations/dementia.html
Centers for Medicare & Medicaid Services. Annual wellness visit health risk assessment. https://www.cms.gov/Outreach-and-Education/Medicare-Learning-Network-MLN/MLNProducts/preventive-services/medicare-wellness-visits.html
Zheng G, Xia R, Zhou W, Tao J, Chen L. Aerobic exercise ameliorates cognitive function in older adults with mild cognitive impairment: a systematic review and meta-analysis of randomised controlled trials. Br J Sports Med. 2016;50(23):1443-1450.
Chertkow H, Massoud F, Nasreddine Z. Diagnosis and treatment of dementia: 3. Mild cognitive impairment and cognitive impairment without dementia. CMAJ. 2008;178(10):1273-1285.
Custodio N, Montesinos R, Lira D, Herrera-Pérez E, Bardales Y, Valeriano-Lorenzo L. Mixed dementia: a review of the evidence. Dement Neuropsychol. 2017;11(4):364-370.
Fu C, Chute DJ, Farag ES, Garakian J, Cummings JL, Vinters HV. Comorbidity in dementia: an autopsy study. Arch Pathol Lab Med. 2004;128(1):32-38.
Alzheimer’s Association. 2022 Alzheimer’s disease facts and figures. https://www.alz.org/alzheimers-dementia/facts-figures
Bir SC, Khan MW, Javalkar V, Toledo EG, Kelley RE. Emerging concepts in vascular dementia: a review. J Stroke Cerebrovasc Dis. 2021;30(8):105864.
Prasad S, Katta MR, Abhishek S. Recent advances in Lewy body dementia: a comprehensive review. Dis Mon. 2023;69(5):101441.
Abubakar MB, Sanusi KO, Ugusman A. Alzheimer’s disease: an update and insights into pathophysiology. Front Aging Neurosci. 2022;14:742408.
Baumgart M, Snyder HM, Carrillo MC, Fazio S, Kim H, Johns H. Summary of the evidence on modifiable risk factors for cognitive decline and dementia: a population-based perspective. Alzheimers Dement. 2015;11(6):718-726.
Zheng Y-B, Shi L, Zhu XM. Anticholinergic drugs and the risk of dementia: a systematic review and meta-analysis. Neurosci Biobehav Rev. 2021;127:296-306.
Wolters FJ, Ikram MA. Epidemiology of vascular dementia. Arterioscler Thromb Vasc Biol. 2019;39(8):1542-1549.
Zaccai J, McCracken C, Brayne C. A systematic review of prevalence and incidence studies of dementia with Lewy bodies. Age Ageing. 2005;34(6):561-566.
Koros C, Stefanis L, Scarmeas N. Parkinsonism and dementia. J Neurol Sci. 2022;433:120015.
Orme T, Guerreiro R, Bras J. The genetics of dementia with Lewy bodies: current understanding and future directions. Curr Neurol Neurosci Rep. 2018;18(10):67.
Crane PK, Gibbons LE, Dams-O’Connor K. Association of traumatic brain injury with late-life neurodegenerative conditions and neuropathologic findings. JAMA Neurol. 2016;73(9):1062-1069.
McKeith IG, Boeve BF, Dickson DW. Diagnosis and management of dementia with Lewy bodies: Fourth Consensus Report of the DLB Consortium. Neurology. 2017;89(1):88-100.
Hogan DB, Jetté N, Fiest KM. The prevalence and incidence of frontotemporal dementia: a systematic review. Can J Neurol Sci. 2016;43(Suppl 1):S96-S109.
Tartaglia MC, Mackenzie IRA. Recent advances in frontotemporal dementia. Can J Neurol Sci. 2023;50(4):485-494.
Goldman JS, Farmer JM, Wood EM. Comparison of family histories in FTLD subtypes and related tauopathies. Neurology. 2005;65(11):1817-1819.
Rasmussen H, Stordal E, Rosness TA. Risk factors for frontotemporal dementia. Tidsskr Nor Laegeforen. 2018;138(14) ):10.4045/tidsskr.17.0763.
Falk N, Cole A, Meredith TJ. Evaluation of suspected dementia. Am Fam Physician. 2018;97(6):398-405.
Arvanitakis Z, Shah RC, Bennett DA. Diagnosis and management of dementia: review. JAMA. 2019;322(16):1589-1599.
Park M, Unützer J. Geriatric depression in primary care. Psychiatr Clin North Am. 2011;34(2):469-487.
Krishnamoorthy Y, Rajaa S, Rehman T. Diagnostic accuracy of various forms of geriatric depression scale for screening of depression among older adults: systematic review and meta-analysis. Arch Gerontol Geriatr. 2020;87:104002.
Zhang H, Wang S, Wang L, Yi X, Jia X, Jia C. Comparison of the Geriatric Depression Scale-15 and the Patient Health Questionnaire-9 for screening depression in older adults. Geriatr Gerontol Int. 2020;20(2):138-143.
- Simel DL, Holsinger T, Deveau J, Boustani M, Williams JW. Jr. Dementia. In: Simel DL, Rennie D, eds. The Rational Clinical Examination: Evidence-Based Clinical Diagnosis. McGraw Hill; 2009.
Oh ES, Fong TG, Hshieh TT, Inouye SK. Delirium in older persons: advances in diagnosis and treatment. JAMA. 2017;318(12):1161-1174.
National Institute for Health and Care Excellence. Delirium: prevention, diagnosis and management in hospital and long-term care. http://www.nice.org.uk/cg103
Wright AEH, Harrell HE. Physical examination in the evaluation of dementia. Med Clin North Am. 2022;106(3):471-482.
Santacruz KS, Swagerty D. Early diagnosis of dementia. Am Fam Physician. 2001;63(4):703-713.
Yamada M, Komatsu J, Nakamura K. Diagnostic criteria for dementia with Lewy bodies: updates and future directions. J Mov Disord. 2020;13(1):1-10.
Beauchet O, Annweiler C, Callisaya ML. Poor gait performance and prediction of dementia: results from a meta-analysis. J Am Med Dir Assoc. 2016;17(6):482-490.
Knopman DS, DeKosky ST, Cummings JL. Practice parameter: diagnosis of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2001;56(9):1143-1153.
Galvin JE, Sadowsky CH. Practical guidelines for the recognition and diagnosis of dementia. J Am Board Fam Med. 2012;25(3):367-382.
Oh ES, Rabins PV. Dementia. Ann Intern Med. 2019;171(5):ITC33-ITC48.
Bekris LM, Yu CE, Bird TD, Tsuang DW. Genetics of Alzheimer disease. J Geriatr Psychiatry Neurol. 2010;23(4):213-227.
Mayeux R, Saunders AM, Shea S. Utility of the apolipoprotein E genotype in the diagnosis of Alzheimer’s disease. N Engl J Med. 1998;338(8):506-511. 1998;338(18):1325.
Ertekin-Taner N. Genetics of Alzheimer’s disease: a centennial review. Neurol Clin. 2007;25(3):611-v.
Teunissen CE, Verberk IMW, Thijssen EH. Blood-based biomarkers for Alzheimer’s disease: towards clinical implementation. Lancet Neurol. 2022;21(1):66-77.
Moonis G, Subramaniam RM, Trofimova A. ACR Appropriateness Criteria® Dementia. J Am Coll Radiol. 2020;17(5S):S100-S112.
Johnson KA, Minoshima S, Bohnen NI. Appropriate use criteria for amyloid PET: a report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer’s Association. Alzheimers Dement. 2013;9(1):e-16.
McCleery J, Laverty J, Quinn TJ. Diagnostic test accuracy of telehealth assessment for dementia and mild cognitive impairment. Cochrane Database Syst Rev. 2021(7):CD013786.
MoCA Cognition. Montreal Cognitive Assessment. https://mocacognition.com/paper/
Watt JA, Lane NE, Veroniki AA. Diagnostic accuracy of virtual cognitive assessment and testing: systematic review and meta-analysis. J Am Geriatr Soc. 2021;69(6):1429-1440.
Geddes MR, O’Connell ME, Fisk JD, Gauthier S, Camicioli R, Ismail Z. Remote cognitive and behavioral assessment: report of the Alzheimer Society of Canada Task Force on Dementia Care Best Practices for COVID-19. Alzheimers Dement (Amst). 2020;12(1):e12111.
Janssen JC, Beck JA, Campbell TA. Early onset familial Alzheimer’s disease: mutation frequency in 31 families. Neurology. 2003;60(2):235-239.
Rutjes AW, Denton DA, Di Nisio M. Vitamin and mineral supplementation for maintaining cognitive function in cognitively healthy people in mid and late life. Cochrane Database Syst Rev. 2018(12):CD011906.
McCleery J, Abraham RP, Denton DA. Vitamin and mineral supplementation for preventing dementia or delaying cognitive decline in people with mild cognitive impairment. Cochrane Database Syst Rev. 2018(11):CD011905.
Du Y, Liang F, Zhang L, Liu J, Dou H. Vitamin D supplement for prevention of Alzheimer’s disease: a systematic review and meta-analysis. Am J Ther. 2020;28(6):e638-e648.
Farina N, Llewellyn D, Isaac MGEKN, Tabet N. Vitamin E for Alzheimer’s dementia and mild cognitive impairment. Cochrane Database Syst Rev. 2017(4):CD002854.
Birks J, Grimley Evans J. Ginkgo biloba for cognitive impairment and dementia. Cochrane Database Syst Rev. 2009(1):CD003120.
Alex A, Abbott KA, McEvoy M, Schofield PW, Garg ML. Long-chain omega-3 polyunsaturated fatty acids and cognitive decline in non-demented adults: a systematic review and meta-analysis. Nutr Rev. 2020;78(7):563-578.
Burckhardt M, Herke M, Wustmann T, Watzke S, Langer G, Fink A. Omega-3 fatty acids for the treatment of dementia. Cochrane Database Syst Rev. 2016(4):CD009002.
Moran DL, Underwood MY, Gabourie TA, Lerner KC. Effects of a supplement containing apoaequorin on verbal learning in older adults in the community. Adv Mind Body Med. 2016;30(1):4-11.
- Lerner KC. Madison Memory Study: a randomized, double-blinded, placebo-controlled trial of apoaequorin in community-dwelling, older adults. Clinical Trial Synopsis Identifier: QB-0011. https://cdn.shopify.com/s/files/1/0583/2268/2043/files/Clinical-TrialSynopsis-cmk816.pdf
Costa AC, Joaquim HPG, Pedrazzi JFC, Pain AO, Duque G, Aprahamian I. Cannabinoids in late life Parkinson’s disease and dementia: biological pathways and clinical challenges. Brain Sci. 2022;12(12):1596.
Bahji A, Meyyappan AC, Hawken ER. Cannabinoids for the neuropsychiatric symptoms of dementia: a systematic review and meta-analysis. Can J Psychiatry. 2020;65(6):365-376.
Bosnjak Kuharic D, Markovic D, Brkovic T. Cannabinoids for the treatment of dementia. Cochrane Database Syst Rev. 2021(9):CD012820.
Wu M, Li M, Yuan J. Postmenopausal hormone therapy and Alzheimer’s disease, dementia, and Parkinson’s disease: a systematic review and time-response meta-analysis. Pharmacol Res. 2020;155:104693.
Mangione CM, Barry MJ, Nicholson WK. Hormone therapy for the primary prevention of chronic conditions in postmenopausal persons. JAMA. 2022;328(17):1740-1746.
Birks J, Flicker L. Selegiline for Alzheimer’s disease. Cochrane Database Syst Rev. 2000(2):CD000442.
Tabatabaei Malazy O, Bandarian F, Qorbani M. The effect of metformin on cognitive function: a systematic review and meta-analysis. J Psychopharmacol. 2022;36(6):666-679.
Jordan F, Quinn TJ, McGuinness B. Aspirin and other non-steroidal anti-inflammatory drugs for the prevention of dementia. Cochrane Database Syst Rev. 2020(4):CD011459.
Ismail Z, Black SE, Camicioli R. Recommendations of the 5th Canadian Consensus Conference on the Diagnosis and Treatment of Dementia. Alzheimers Dement. 2020;16(8):1182-1195.
World Health Organization. Risk reduction of cognitive decline and dementia: WHO guidelines. https://www.who.int/publications/i/item/9789241550543
Marucci G, Buccioni M, Ben DD, Lambertucci C, Volpini R, Amenta F. Efficacy of acetylcholinesterase inhibitors in Alzheimer’s disease. Neuropharmacology. 2021;190:108352.
Rolinski M, Fox C, Maidment I, McShane R. Cholinesterase inhibitors for dementia with Lewy bodies, Parkinson’s disease dementia and cognitive impairment in Parkinson’s disease. Cochrane Database Syst Rev. 2012(3):CD006504.
Battle CE, Abdul-Rahim AH, Shenkin SD, Hewitt J, Quinn TJ. Cholinesterase inhibitors for vascular dementia and other vascular cognitive impairments: a network meta-analysis. Cochrane Database Syst Rev. 2021(2):CD013306.
McShane R, Westby MJ, Roberts E. Memantine for dementia. Cochrane Database Syst Rev. 2019(3):CD003154.
Shi X, Ren G, Cui Y, Xu Z. Comparative efficacy and acceptability of cholinesterase inhibitors and memantine based on dosage in patients with vascular cognitive impairment: a network meta-analysis. Curr Alzheimer Res. 2022;19(2):133-145.
Wang HF, Yu JT, Tang SW. Efficacy and safety of cholinesterase inhibitors and memantine in cognitive impairment in Parkinson’s disease, Parkinson’s disease dementia, and dementia with Lewy bodies: systematic review with meta-analysis and trial sequential analysis. J Neurol Neurosurg Psychiatry. 2015;86(2):135-143.
Herrmann N, Ismail Z, Collins R. CCCDTD5 recommendations on the deprescribing of cognitive enhancers in dementia. Alzheimers Dement (N Y). 2022;8(1):e12099.
Parsons C, Lim WY, Loy C. Withdrawal or continuation of cholinesterase inhibitors or memantine or both, in people with dementia. Cochrane Database Syst Rev. 2021(2):CD009081.
Vaz M, Silva V, Monteiro C, Silvestre S. Role of aducanumab in the treatment of Alzheimer’s disease: challenges and opportunities. Clin Interv Aging. 2022;17:797-810.
Alexander GC, Emerson S, Kesselheim AS. Evaluation of aducanumab for Alzheimer disease: scientific evidence and regulatory review involving efficacy, safety, and futility. JAMA. 2021;325(17):1717-1718.
Day GS, Scarmeas N, Dubinsky R. Aducanumab use in symptomatic Alzheimer disease evidence in focus: a report of the AAN Guidelines Subcommittee. Neurology. 2022;98(15):619-631.
Cummings J, Aisen P, Apostolova LG, Atri A, Salloway S, Weiner M. Aducanumab: appropriate use recommendations. J Prev Alzheimers Dis. 2021;8(4):398-410.
- Leqembi. Package insert. Leqembi. Package insert. Eisai Inc. 2023.
Bessey LJ, Walaszek A. Management of behavioral and psychological symptoms of dementia. Curr Psychiatry Rep. 2019;21(8):66.
Kales HC, Gitlin LN, Lyketsos CG. Management of neuropsychiatric symptoms of dementia in clinical settings: recommendations from a multidisciplinary expert panel. J Am Geriatr Soc. 2014;62(4):762-769.
Ralph SJ, Espinet AJ. Increased all-cause mortality by antipsychotic drugs: updated review and meta-analysis in dementia and general mental health care. J Alzheimers Dis Rep. 2018;2(1):1-26.
Carrarini C, Russo M, Dono F. Agitation and dementia: prevention and treatment strategies in acute and chronic conditions. Front Neurol. 2021;12:644317.
Mühlbauer V, Möhler R, Dichter MN, Zuidema SU, Köpke S, Luijendijk HJ. Antipsychotics for agitation and psychosis in people with Alzheimer’s disease and vascular dementia. Cochrane Database Syst Rev. 2021(12):CD013304.
Reus VI, Fochtmann LJ, Eyler AE. The American Psychiatric Association practice guideline on the use of antipsychotics to treat agitation or psychosis in patients with dementia. Am J Psychiatry. 2016;173(5):543-546.
Bjerre LM, Farrell B, Hogel M. Deprescribing antipsychotics for behavioural and psychological symptoms of dementia and insomnia: evidence-based clinical practice guideline. Can Fam Physician. 2018;64(1):17-27.
Chen A, Copeli F, Metzger E, Cloutier A, Osser DN. The Psycho-pharmacology Algorithm Project at the Harvard South Shore Program: an update on management of behavioral and psychological symptoms in dementia. Psychiatry Res. 2021;295:113641.
Baillon SF, Narayana U, Luxenberg JS, Clifton AV. Valproate preparations for agitation in dementia. Cochrane Database Syst Rev. 2018(10):CD003945.
- Gallagher D, Herrmann N. Antiepileptic drugs for the treatment of agitation and aggression in dementia: do they have a place in therapy? Drugs. 2014;74(15):1747-1755.
Jeremic D, Jiménez-Díaz L, Navarro-López JD. Past, present and future of therapeutic strategies against amyloid-ß peptides in Alzheimer’s disease: a systematic review. Ageing Res Rev. 2021;72:101496.
Eggenberger E, Heimerl K, Bennett MI. Communication skills training in dementia care: a systematic review of effectiveness, training content, and didactic methods in different care settings. Int Psychogeriatr. 2013;25(3):345-358.
Banovic S, Zunic LJ, Sinanovic O. Communication difficulties as a result of dementia. Mater Sociomed. 2018;30(3):221-224.
Eisenmann Y, Golla H, Schmidt H, Voltz R, Perrar KM. Palliative care in advanced dementia. Front Psychiatry. 2020;11:699.
Aworinde J, Ellis-Smith C, Gillam J. How do person-centered outcome measures enable shared decision-making for people with dementia and family carers?–A systematic review. Alzheimers Dement (N Y). 2022;8(1):e12304.
Alzheimer’s Association. Communication and Alzheimer’s. https://www.alz.org/help-support/caregiving/daily-care/communications
Smith R, Martin A, Wright T, Hulbert S, Hatzidimitriadou E. Integrated dementia care: a qualitative evidence synthesis of the experiences of people living with dementia, informal carers and healthcare professionals. Arch Gerontol Geriatr. 2021;97:104471.
Podgorski CA, Anderson SD, Parmar J. A biopsychosocial-ecological framework for family-framed dementia care. Front Psychiatry. 2021;12:744806.
Connors MH, Seeher K, Teixeira-Pinto A, Woodward M, Ames D, Brodaty H. Dementia and caregiver burden: a three-year longitudinal study. Int J Geriatr Psychiatry. 2020;35(2):250-258.
Backhouse T, Ruston A, Killett A, Ward R, Rose-Hunt J, Mioshi E. Risks and risk mitigation in homecare for people with dementia-a two-sided matter: a systematic review. Health Soc Care Community. 2022;30(6):2037-2056.
Sheikh AB, Javed N, Ijaz Z, Leyba K, Barrett E, Dunn A. Easing dementia caregiver burden, addressing interpersonal violence. J Fam Pract. 2022;71(1):E1-E8.
Lin PJ, Daly AT, Olchanski N. Dementia diagnosis disparities by race and ethnicity. Med Care. 2021;59(8):679-686.
Balls-Berry JJE, Babulal GM. Health disparities in dementia. Continuum (Minneap Minn). 2022;28(3):872-884.
Aranda MP, Kremer IN, Hinton L. Impact of dementia: health disparities, population trends, care interventions, and economic costs. J Am Geriatr Soc. 2021;69(7):1774-1783.
- Edemekong PF, Bomgaars DL, Sukumaran S, Schoo C. Activities of daily living. StatPearls Publishing; 2023. https://www.ncbi.nlm.nih.gov/books/NBK470404/
Wallace M, Shelkey M. Katz Index of Independence in Activities of Daily Living (ADL). Hartford Inst Geriatr Nurs. 2007;2.
Lawton MP. The functional assessment of elderly people. J Am Geriatr Soc. 1971;19(6):465-481.
Graf C. The Lawton Instrumental Activities of Daily Living (IADL) Scale. Hartford Inst Geriatr Nurs. 2007;23.
Katz S, Downs TD, Cash HR, Grotz RC. Progress in development of the index of ADL. Gerontologist. 1970;10(1):20-30.
Hamdy RC, Kinser A, Kendall-Wilson T, Depelteau A, Whalen K, Culp J. Driving and patients with dementia. Gerontol Geriatr Med. 2018;4:2333721418777085.
Holden A, Pusey H. The impact of driving cessation for people with dementia—an integrative review. Dementia (London). 2021;20(3):1105-1123.
Palmer BW, Harmell AL. Assessment of healthcare decision-making capacity. Arch Clin Neuropsychol. 2016;31(6):530-540.
Weisbrod N. Primary palliative care in dementia. Neurotherapeutics. 2022;19(1):143-151.
Darby RR, Dickerson BC. Dementia, decision making, and capacity. Harv Rev Psychiatry. 2017;25(6):270-278.
Piers R, Albers G, Gilissen J. Advance care planning in dementia: recommendations for healthcare professionals. BMC Palliat Care. 2018;17(1):88.
Pennington C, Davey K, Ter Meulen R, Coulthard E, Kehoe PG. Tools for testing decision-making capacity in dementia. Age Ageing. 2018;47(6):778-784.
Leatherman ME, Goethe KE. Substituted decision making: elder guardianship. J Psychiatr Pract. 2009;15(6):470-476.
Centers for Medicare & Medicaid Services. Medicare coverage database. Local coverage determination: Hospice Alzheimer’s disease & related disorders, L34567. https://www.cms.gov/medicare-coverage-database/view/lcd.aspx?lcdid=34567
